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The objective of the present study was to describe day of onset and duration of symptoms of Marburg
hemorrhagic fever (MHF), to summarize the treatments applied, and to assess the quality of clinical docu-
mentation. Surveillance and clinical records of 77 patients with MHF cases were reviewed. Initial symptoms
included fever, headache, general pain, nausea, vomiting, and anorexia (median day of onset, day 1–2),followed
by hemorrhagic manifestations (day 5–8+), and terminal symptoms included confusion, agitation, coma,
anuria, and shock. Treatment in isolation wards was acceptable, but the quality of clinical documentation was
unsatisfactory. Improved clinical documentation is necessary for a basic evaluation of supportive treatment.
In Durba and Watsa, both situatedinWatsaHealthZone,
northeastern Democratic Republic of the Congo (DRC),
a Marburg hemorrhagic fever (MHF) outbreakoccurred
between October 1998 and September 2000. A detailed
description of the Marburg hemorrhagic fever outbreaks
in the Durba area has been published elsewhere [1]. In
summary, primary cases were found among goldminers,
and secondary cases were found among family members
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and health workers. The total number of cases was 154,
with a case fatality rate of 83%. In May 1999, an inter-
national team, coordinated by the World Health Orga-
nization (WHO), arrived in Durba to investigate and
respond to the epidemic [1, 2].
Before the Durba outbreak, the knowledge of clinical
manifestations of and treatment options for Marburg
virus infection was based on observations of 39 patients
in Europe only [3–8]. The primary objective of the
present article is to extend the knowledge base by re-
porting clinical information on patients with Marburg
virus infection in the 1998–2000 outbreaks in Durba
and Watsa, DRC. A secondary objective is to assess the
quality of the clinical documentation of these patients.
METHODS
In this article, we report on 51 patients with conﬁrmed
cases of MHF (including 3 cases identiﬁed retrospec-
tively) and 26 patients with probable MHF. Probable
cases were patients with suspected MHF who were ep-
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a conﬁrmed case. A patient with conﬁrmed MHF was deﬁned
as someone who fulﬁlled the deﬁnition of having a probable
case and had at least 1 laboratory test result positive for Mar-
burg virus (ELISA antigen detection, ELISA IgM antibody de-
tection, virus culture, reverse-transcription polymerase chain
reaction, and/or immunohistochemical analysis). Patients with
suspected MHF who were not epidemiologically linked were
not included in our analysis because of the relative uncertainty
of the diagnoses.
We extracted data from surveillance records on symptom
onset and duration. For patients who had sought health care,
we extracted data from clinical records on symptom onset,
duration, and patterns, as well as on treatment received.
To assess the quality of the clinical documentation, we de-
ﬁned the assessment of the following clinical parameters to be
essential: body temperature (measured at least twice daily),
pulse rate, respiratory rate, vomiting, diarrhea, dehydration,
bleeding signs (including petechiae), levelofconsciousness,and
pain (assessed at least daily). We considered the assessment of
the following parameters as nonessential but relevant: blood
pressure and urine output. Normally, these parameters also
would have been considered to be essential, but the decontam-
ination of the cuffs is difﬁcult, and the manipulation of po-
tentially contaminated urine is hazardous; therefore, it may be
acceptable not to assess these parameters.
We extracted all data on treatment regimens that were doc-
umented in the clinical records. We deﬁned essentialsystematic
treatment as treatment with antimalarialsandantibiotics,under
the assumption that neither malaria nor bacterial infection
could be ruled out under the given circumstances; in addition,
treatment with analgesics, antipyretics, or antiemetics was clas-
siﬁed as “essential if indicated.” We considered the following
to be not essential but relevant: nasogastric feeding, antiulcer
drugs, and intravenous ﬂuids; for this analysis, intravenous
ﬂuids were not considered to be essential, because they should
be expected to begiven onlyifitcanbedonesafely.Weclassiﬁed
the following as contraindicated: acetylsalicylic acid, nonster-
oidal anti-inﬂammatory drugs, and intramuscular injections.
Note that it would, in our view, be a sensible policy to give
the “essential if indicated” drugs systematically.
RESULTS
In the set of patients we analyzed, 45 (58%) were male, 68
(88%) were adult (15 years of age), 35 (45%) were gold
miners, and 22 (29%) were housewives. The case fatality rate
was 78%, with a median interval of 8 days (range, 2–16 days)
between the onset of symptoms and death.
Completeness and quality of documentation. Surveillance
forms and clinical records were available for 64 and 13 patients,
respectively. It was not uncommon to ﬁnd inconsistencies be-
tween the surveillance and clinical records. In such situations,
we gave preference to the information contained in the clinical
records. Of the 13 clinical records, 2 came close to being case
notes and were too unsystematic for further analysis, and 2
referred to patients who died so shortly after admission that
the clinical record was just about to be started. Thus, only 9
clinical records were available for further analysis, all relating
to hospitalized patients with conﬁrmed MHF.
For these 9 patients, 3 different models of clinical records
were used:
1. A sheet (“tick list”) with 36 clinical parameters, which
were supposed to be assessed on a daily basis. These parameters
included all parameters we considered to be essential and many
more, but they did not include the relevant parameters de-
hydration and respiratory rate. Not only the presence but also
the absence of symptoms was documented (“zero reporting”).
However, there was no room allotted for the documentation
of treatment.
2. A chart on which temperature, pulse rate, respiratory
rate, and blood pressure were supposed to be graphically rep-
resented. There was some empty space at the bottom of the
form, which was used to document the presence of the essential
parameters vomiting and diarrhea but not dehydration, con-
sciousness, pain, bleeding signs, or the relevant parameterurine
output. Most of the empty space was used to document
treatment.
3. A combination of the chartdescribedaboveplusashort
list of essential symptoms. However, because no space was pro-
vided to document treatment, these symptoms—for example,
dehydration—were stroked through and replaced by drug
names, effectively turning model 3 into model 2. Only the
presence of vomiting and diarrhea was documented rather re-
liably; none of the other symptoms were. The absence of symp-
toms was not documented when this model or model 2 was
used.
The documentation of temperature and pulse rate was good,
and that of respiratory rate and blood pressure was satisfactory.
The documentation of symptoms was poor, with the exception
of diarrhea and vomiting. There was no documentation of
dehydration, despite this symptom being crucial for triggering
and monitoring oral or intravenous rehydration therapy. Doc-
umentation of the absence of key symptoms was the exception.
The duration of symptoms was reported in !10% of the clinical
records.
Frequency and succession of symptoms. The frequency of
symptoms at any stage of disease is presented in table 1. The
most frequently seen general symptoms included fever (86%),
fatigue (82%), loss of appetite (77%), severe headache (74%),
nausea/vomiting (73%), and generalized pain (65%); the most
frequently observed hemorrhagic signs were hematemesis
(56%), melena or bloody diarrhea (55%), and bleeding gums
(32%). Restricting the analysis to conﬁrmed cases would haveS150 • JID 2007:196 (Suppl 2) • Colebunders et al.
Table 1. Symptoms in patients with conﬁrmed or probable Marburg hemorrhagic fever (MHF).
Symptom (sorted by frequency)
Total
() N p 77
Patients with
conﬁrmed MHF
() n p 51
Patients with
probable MHF
() n p 26
Patients
who survived
() n p 17
Patients
who died
() n p 60 P
a
Fever 66 (86) 44 (86) 22 (85) 13 (76) 53 (88) .22
General
Fatigue 63 (82) 47 (92) 16 (62) 16 (94) 47 (78) .14
Loss of appetite 59 (77) 44 (86) 15 (58) 15 (88) 44 (73) .20
Severe headache 57 (74) 41 (80) 16 (62) 12 (71) 45 (75) .71
Nausea/vomiting 56 (73) 42 (82) 14 (54) 13 (76) 43 (72) .69
Generalized pain 50 (65) 37 (73) 13 (50) 11 (65) 39 (65) .98
Diarrhea 46 (60) 33 (65) 13 (50) 7 (41) 39 (65) .08
Dyspnea 43 (56) 28 (55) 15 (58) 10 (59) 33 (55) .78
Abdominal pain 41 (53) 29 (57) 12 (46) 6 (35) 35 (58) .09
Sore throat/dysphagia 40 (52) 30 (59) 10 (38) 8 (47) 32 (53) .65
Hiccups 30 (39) 23 (45) 7 (27) 5 (29) 25 (42) .36
Conjunctivitis 28 (36) 21 (41) 7 (27) 3 (18) 25 (42) .07
Chest pain 18 (23) 15 (29) 3 (12) 12 (71) 6 (10) !.01
Lumbar pain 13 (17) 11 (22) 2 (8) 5 (29) 8 (13) .12
Coughing 12 (16) 9 (18) 3 (12) 3 (18) 9 (15) .79
Coma 124 h 1 (1) 1 (2) 0 (0) 0 (0) 1 (2) .59
Hemorrhagic
Any 64 (83) 42 (82) 22 (100) 11 (65) 53 (88) .03
Hematemesis 43 (56) 32 (63) 11 (42) 8 (47) 35 (58) .41
Melena, bloody diarrhea 42 (55) 28 (55) 14 (54) 6 (35) 36 (60) .07
Bleeding gums 25 (32) 16 (31) 9 (35) 3 (18) 22 (37) .14
Epistaxis 15 (19) 8 (16) 7 (27) 2 (12) 13 (22) .36
Bleeding at injection site 11 (14) 8 (16) 3 (12) 0 (0) 11 (18) .06
Hemoptysis 7 (9) 4 (8) 3 (12) 3 (18) 4 (7) .16
Petechiae 4 (5) 3 (6) 1 (4) 1 (6) 3 (5) .89
Vaginal bleeding
b 3 (9) 1 (6) 2 (14) 0 (0) 3 (12) .47
Hematuria 0 (0) 0 (0) 0 (0) 0 (0) 0 (0)
Combinations
Fever plus at least 3 general symptoms 63 (82) 45 (88) 18 (69) 14 (82) 49 (82) 1.0
Fever plus hemorrhage 57 (74) 38 (74) 18 (69) 11 (65) 48 (80) .21
NOTE. Data are no. (%) of patients with a given symptom, unless otherwise indicated.
a x
2 test comparing proportions in survivors and fatalities.
b Denominator contains female patients only.
resulted in exactly the same ranking of symptoms. Virtually all
symptoms were documented more frequently in conﬁrmed
than in probable cases. The most signiﬁcant predictors of a
fatal outcome ( , x
2 test) were diarrhea, abdominal pain, P ! .1
conjunctivitis, absence of chest pain, melena/bloody diarrhea,
and bleeding at the injection site.
For each symptom, table 2 presents the median day of onset
and the median duration, as well as whether symptoms, which
lasted longer than 2 days, occurred on consecutive days. The
description of 2 typical cases of MHF can be found in the
Appendix, which appears only in the online edition of the
Journal.
Disease usually started with fever and severe headache on
day 1, followed by fatigue, generalized pain, and loss of appetite
on day 2. Nausea, vomiting, and diarrhea were lead symptoms
for day 3, and dysphasia, dyspnea, and conjunctivitis typically
marked day 4. Minor hemorrhage (e.g., epistaxis) typically
started on day 3–4, and major hemorrhage (melena, bloody
diarrhea, and hematemesis) started on day 5–7. Coma lasting
124 h occurred in only 1 patient, starting on day 6. The patient
did not regain consciousness and died on day 10.
Treatment. A total of 8 records included data on treatment.
These data were sometimes documented in speciﬁc forms but
were often scribbled in the margins of temperature sheets. All
of these records belonged to patients whose MHF had been
diagnosed on clinical grounds before laboratory conﬁrmationMHF in Durba and Watsa • JID 2007:196 (Suppl 2) • S151
Table 2. Date of onset, duration, and continuity of symptoms in 77 patients with conﬁrmed and probable Marburg hemorrhagic fever
(MHF).
Symptom (sorted by
day of onset)
Patients, no. Day of onset Duration of symptom
Pattern
Had
symptom
Received
health care
No. of records
with data
Day of onset,
median
No. of records
with data
Duration of
symptom,
median, days
Fever 66 54 49 1 8 2 Intermittent
General symptoms
Severe headache 57 48 44 1 2 3 Intermittent
Fatigue 63 50 50 2 3 2 Intermittent
Chest pain 18 15 11 2 4 2.5 Unknown
Generalized pain 50 42 40 2 0 … …
Loss of appetite 59 49 49 2 5 1 Intermittent
Nausea/vomiting 56 48 44 2.5 8 3 Intermittent
Coughing 12 11 10 2.5 4 2.5 Unknown
Diarrhea 46 36 38 3 5 3 Continuous
a
Abdominal pain 41 33 37 3 1 1 …
Lumbar pain 13 9 7 4 3 2 Continuous
Sore throat/dysphagia 40 30 32 4 5 1 Continuous
Dyspnea 43 32 32 4 1 1 …
Conjunctivitis 28 21 22 4 0 … …
Hiccups 30 24 23 6 0 … …
Coma 124 h 1 1 1 6 0 … …
Hemorrhagic symptoms
Any 64 59 64 5.5 6 3 …
Epistaxis 15 14 11 3 0 … …
Bleeding gums 25 20 21 4 0 … …
Melena 42 32 33 5 1 6 …
Hematemesis 43 37 37 5 5 2 Continuous
Vaginal bleeding
b 33 2 6 0 … …
Hemoptysis 7 6 3 7 0 … …
Petechiae 4 3 2 9 0 … …
Death 60 45 59 8 … … …
a In 4 of 5 patients.
b Denominator contains female subjects only.
was available. All patientssystematicallyreceivedantimalarialand
antibiotic treatment, the latter often in combination therapyand
sometimes in polypharmacy (e.g., the combination of tetracy-
cline, cotrimoxazole, chloramphenicol, and metronidazol).
The only analgesic administered was acetaminophen, rather
generously, possibly also for its antipyretic characteristics. It is
impossible to judge from the recordswhetherstrongeranalgesia
was indicated occasionally or whether all patients had adequate
pain relief. Antiemetics (chlorpromazine or metoclopramide)
were given rather frequently, as was aluminium hydroxide as
an antacid. Almost all patients received intravenous ﬂuids. Be-
cause no data on dehydration were collected, we do not know
whether this was done to prevent or to treat dehydration. Na-
sogastric feeding was not practiced. No contraindicated drugs
or types of applications were used in the treatment of these 8
patients.
DISCUSSION
We analyzed the clinical and surveillance records of 77 patients,
51 of whom had conﬁrmed MHF and 26 of whomhadprobable
MHF. The type of clinical manifestations and the course of
disease in patients with Marburg virus infection in DRC were
similar to those previously reported in other patients withMar-
burg virus and Ebola virus infection [3–9]. The illnessgenerally
starts with fever, malaise, muscle pain, and headache. Two to
4 days after onset,gastrointestinalsymptoms(nausea,vomiting,
and diarrhea), as well as conjunctival injection and rash, can
be observed. Sore throat/dysphagiawasnotedtooccurgenerally
at around day 4, but 2 of us (R.C. and B.J.) felt that a sore
throat might already have been present on days 2–4. Death
typically occurred after 8–10 days; diarrhea, bloody diarrhea,
and abdominal pain, as well as conjunctivitis andbleedingfromS152 • JID 2007:196 (Suppl 2) • Colebunders et al.
Figure 1. Proposed case report form for future Marburg/Ebola hem-
orrhagic fever outbreaks, based on a model created by Me ´dicins Sans
Frontie `res for the 2005 outbreak in Uige, Angola. The ﬁgure is available
in its entirety in the online edition of the Journal of Infectious Diseases.
injection sites, were associatedwith afataloutcome.Theclinical
picture we found in Durba and Watsa corresponds to what was
seen in Uige, Angola, in 2005 (Paul Roddy, MSFSpain,personal
communication).
The most striking difference between the patients in our
study and those in Europe is the signiﬁcantly higher frequency
of hemorrhagic manifestations (83% vs. 34%; , Fisher’s P ! .001
exact test) and fatal outcomes (78% vs 22%; ) in DRC P ! .001
[3, 4]. Possible explanations for this ﬁnding include, among
others, differences in virus pathogenicity, infectious dose, and
inoculation route and in the availability and quality of sup-
portive care.
The patients systematically received antimalarials and anti-
biotics, which is appropriate when malaria and bacterial infec-
tion cannot be ruled out because of the absence of high-level
biosafety laboratory facilities. Antipyretics, antiemetics, and
antacids were used generously, which is probably appropriate;
the question of whether more powerful analgesia might oc-
casionally have been indicated remains unanswered. Intrave-
nous ﬂuids were given frequently, despite the fact that their
unproven effectiveness and the biohazard they impose have
caused some to question their use. In Watsa, no occupational
transmission occurred on the isolation wards, except in 1 in-
cident, when an auxiliary midwife caring for an ill relative
refused to use protective gear [10].
Case-fatality rates did not differ signiﬁcantly between pa-
tients who received or did not receive health care (45 [75%]
of 60 vs. 11 [65%] of 17; , Fisher’s exact test). This crude P p .5
comparison should not be interpreted as evidence for the in-
effectiveness of supportive and symptomatictreatment,because
there is hardly any information about disease severity in both
groups.
We found the clinical documentation of patients with MHF
to be missing, incomplete, and of low quality. It was apparent
that those health workers who used clinical records had un-
dertaken considerable efforts to document the clinical course,
but they lacked guidance on what information is relevant and
the proper forms to achieve decent documentation. Sadly, this
outbreak is no exception in this respect: since the Ebola hem-
orrhagic fever outbreak in Kikwit in 1995, 11 ﬁloviral hem-
orrhagic fever outbreaks with 11200 patients have been reg-
istered, and no clinical data have been published since Kikwit.
Of course, only a minority of patients have been treated in
isolation wards—but 1100 have been treated in such wards,
and study of these patients could have provided valuable in-
formation.Even whenspeciﬁcdiagnosticlaboratorieshavebeen
put in place during an outbreak, laboratory facilities for chem-
istry and hematology have never been available. The conse-
quence is that we do not knowwhichcomponentsofsupportive
and symptomatic care are given in which situation and how
effective they are. Although there is discussion about the fea-
sibility of trials under outbreak conditions to evaluate inno-
vative treatments, we lack basic information about the clinical
manifestations of the disease (e.g., the number of patients who
survive coma while their ﬂuid and electrolyte balance has been
maintained by standard intravenous liquids).
RECOMMENDATION
Setting standards is the mandate of WHO, and standard sur-
veillance and record forms for clinical documentation are ur-
gently needed. Given that only a few organizations are involved
in providing clinical care to patients with ﬁloviral hemorrhagic
fever, it should be possible to agree on what data need to be
collected and which tools to use. Figure 1 shows a case report
form that we propose for use in future Marburg/Ebola hem-
orrhagic fever outbreaks. This form is based on a model that
was created by MSF for the 2005 outbreak in Uiga, Angola.
Analysis and publication must follow if the collection of data
is to be a useful exercise. Given the limited number of patients
per outbreak, pooling of data will possibly allowmorestatistical
power and insight to be gained. The recent severe acute re-
spiratory syndrome outbreak has demonstrated how powerful
international collaboration can be if short-term institutional
interests are put aside.
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